BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation

Frontiers in Cellular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Manning, Elizabeth E ^a,b   van den Buuse, Maarten ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BDNF; Methamphetamine; Prepulse inhibition; Schizophrenia

Indexed keywords

APOMORPHINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENDOPHENOTYPE; FEMALE; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; SENSORY GATING; SEX DIFFERENCE; STARTLE REFLEX;

EID: 84878431731     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00092     Document Type: Article

References (75)

1. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., Van Dyck, C.H., Charney, D.S., Innis, R.B., and Laruelle, M. (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155, 761-767.
2. Angelucci, F., Brene, S., and Mathe, A.A. (2005). BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10, 345-352.
3. Angelucci, F., Gruber, S.H., El Khoury, A., Tonali, P.A., and Mathe, A.A. (2007). Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur Neuropsychopharmacol 17, 756-762.
4. Arai, S., Takuma, K., Mizoguchi, H., Ibi, D., Nagai, T., Takahashi, K., Kamei, H., Nabeshima, T., and Yamada, K. (2008). Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen. Neuropsychopharmacol 33, 3164-3175.
5. Bahi, A., Boyer, F., Chandrasekar, V., and Dreyer, J.L. (2008). Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats. Psychopharmacology (Berl) 199, 169-182.
6. Bosse, K.E., Maina, F.K., Birbeck, J.A., France, M.M., Roberts, J.J., Colombo, M.L., and Mathews, T.A. (2012). Aberrant striatal dopamine transmitter dynamics in brainderived neurotrophic factor-deficient mice. J Neurochem 120, 385-395.
7. Callaghan, R.C., Cunningham, J.K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., Boileau, I., and Kish, S.J. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry 169, 389-396.
8. Caspi, A., and Moffitt, T.E. (2006). Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7, 583-590.
9. Chao, H.M., Kao, H.T., and Porton, B. (2008). BDNF Val66Met variant and age of onset in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B, 505-506.
10. Chao, Y.L., Chen, H.H., and Chen, C.H. (2012). Effects of repeated electroconvulsive shock on methamphetamine-induced behavioral abnormalities in mice. Brain Stimul 5, 393-401.
11. Chavez, C., Gogos, A., Jones, M.E., and Van Den Buuse, M. (2009). Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters. Psychopharmacology (Berl) 206, 267-279.
12. Chen, C.K., Lin, S.K., Sham, P.C., Ball, D., Loh El, W., and Murray, R.M. (2005). Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 136B, 87-91.
13. Chen, C.K., Lin, S.K., Sham, P.C., Ball, D., Loh, E.W., Hsiao, C.C., Chiang, Y.L., Ree, S.C., Lee, C.H., and Murray, R.M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 33, 1407-1414.
14. Coppola, V., and Tessarollo, L. (2004). Control of hyperphagia prevents obesity in BDNF heterozygous mice. Neuroreport 15, 2665-2668.
15. Daws, L.C., Munn, J.L., Valdez, M.F., Frosto-Burke, T., and Hensler, J.G. (2007). Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J Neurochem 101, 641-651.
16. Deltheil, T., Guiard, B.P., Cerdan, J., David, D.J., Tanaka, K.F., Reperant, C., Guilloux, J.P., Coudore, F., Hen, R., and Gardier, A.M. (2008). Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 55, 1006-1014.
17. Dluzen, D.E., Story, G.M., Xu, K., Kucera, J., and Walro, J.M. (1999). Alterations in nigrostriatal dopaminergic function within BDNF mutant mice. Exp Neurol 160, 500-507.
18. Duan, W., Guo, Z., Jiang, H., Ware, M., and Mattson, M.P. (2003). Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 144, 2446-2453.
19. Duman, C.H., Schlesinger, L., Kodama, M., Russell, D.S., and Duman, R.S. (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61, 661-670.
20. Duman, C.H., Schlesinger, L., Russell, D.S., and Duman, R.S. (2008). Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res 1199, 148-158.
21. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., and Swerdlow, N.R. (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117-154.
22. Goldstein, J.M., Seidman, L.J., Goodman, J.M., Koren, D., Lee, H., Weintraub, S., and Tsuang, M.T. (1998). Are there sex differences in neuropsychological functions among patients with schizophrenia? Am J Psychiatry 155, 1358-1364.
23. Gorski, J.A., Balogh, S.A., Wehner, J.M., and Jones, K.R. (2003). Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121, 341-354.
24. Gratacos, M., Gonzalez, J.R., Mercader, J.M., De Cid, R., Urretavizcaya, M., and Estivill, X. (2007). Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61, 911-922.
25. Green, M.J., Matheson, S.L., Shepherd, A., Weickert, C.S., and Carr, V.J. (2011). Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with metaanalysis. Mol Psychiatry 16, 960-972.
26. Guiard, B.P., David, D.J., Deltheil, T., Chenu, F., Le Maitre, E., Renoir, T., Leroux-Nicollet, I., Sokoloff, P., Lanfumey, L., Hamon, M., Andrews, A.M., Hen, R., and Gardier, A.M. (2008). Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int J Neuropsychopharmacol 11, 79-92.
27. Gururajan, A., Manning, E.E., Klug, M., and Van Den Buuse, M. (2012). Drugs of abuse and increased risk of psychosis development. Aust N Z J Psychiatry 46, 1120-1135.
28. Hadamitzky, M., Markou, A., and Kuczenski, R. (2011). Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res 217, 386-390.
29. Hafner, H., Maurer, K., Loffler, W., and Riecher-Rossler, A. (1993). The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162, 80-86.
30. Hall, D.A., Stanis, J.J., Marquez Avila, H., and Gulley, J.M. (2008). A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 195, 469-478.
31. Hall, F.S., Drgonova, J., Goeb, M., and Uhl, G.R. (2003). Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacol 28, 1485-1490.
32. Hashimoto, T., Bergen, S.E., Nguyen, Q.L., Xu, B., Monteggia, L.M., Pierri, J.N., Sun, Z., Sampson, A.R., and Lewis, D.A. (2005). Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25, 372-383.
33. Hill, R.A. (2012). Interaction of sex steroid hormones and brain-derived neurotrophic factortyrosine kinase B signalling: relevance to schizophrenia and depression. J Neuroendocrinol 24, 1553-1561.
34. Hill, R.A., and Van Den Buuse, M. (2011). Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res 1384, 51-60.
35. Hill, R.A., Wu, Y.W., Kwek, P., and Van Den Buuse, M. (2012). Modulatory effects of sex steroid hormones on brain-derived neurotrophic factor-tyrosine kinase B expression during adolescent development in C57Bl/6 mice. J Neuroendocrinol 24, 774-788.
36. Ho, B.C., Milev, P., O'leary, D.S., Librant, A., Andreasen, N.C., and Wassink, T.H. (2006). Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 63, 731-740.
37. Ibarguen-Vargas, Y., Surget, A., Vourc'h, P., Leman, S., Andres, C.R., Gardier, A.M., and Belzung, C. (2009). Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 202, 245-251.
38. Kebir, O., Mouaffak, F., Chayet, M., Leroy, S., Tordjman, S., Amado, I., and Krebs, M.O. (2009). Semantic but not phonological verbal fluency associated with BDNF Val66Met polymorphism in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 150B, 441-442.
39. Klug, M., Hill, R.A., Choy, K.H., Kyrios, M., Hannan, A.J., and Van Den Buuse, M. (2012). Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol Dis 46, 722-731.
40. Koolschijn, P.C., Van Haren, N.E., Bakker, S.C., Hoogendoorn, M.L., Hulshoff Pol, H.E., and Kahn, R.S. (2010). Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 20, 1010-1017.
41. Kusljic, S., and Van Den Buuse, M. (2004). Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug-induced locomotor hyperactivity and prepulse inhibition in rats. Eur J Neurosci 20, 3424-3432.
42. Lahti, A.C., Koffel, B., Laporte, D., and Tamminga, C.A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol 13, 9-19.
43. Le Foll, B., Diaz, J., and Sokoloff, P. (2005). A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport 16, 175-178.
44. Lu, W., Zhang, C., Yi, Z., Li, Z., Wu, Z., and Fang, Y. (2012). Association Between BDNF Val66Met Polymorphism and Cognitive Performance in Antipsychotic-Naive Patients with Schizophrenia. J Mol Neurosci.
45. Lyons, W.E., Mamounas, L.A., Ricaurte, G.A., Coppola, V., Reid, S.W., Bora, S.H., Wihler, C., Koliatsos, V.E., and Tessarollo, L. (1999). Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96, 15239-15244.
46. Mcketin, R., Hickey, K., Devlin, K., and Lawrence, K. (2010). The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev 29, 358-363.
47. Narita, M., Aoki, K., Takagi, M., Yajima, Y., and Suzuki, T. (2003). Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119, 767-775.
48. Neves-Pereira, M., Cheung, J.K., Pasdar, A., Zhang, F., Breen, G., Yates, P., Sinclair, M., Crombie, C., Walker, N., and St Clair, D.M. (2005). BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10, 208-212.
49. Numata, S., Ueno, S., Iga, J., Yamauchi, K., Hongwei, S., Ohta, K., Kinouchi, S., Shibuya-Tayoshi, S., Tayoshi, S., Aono, M., Kameoka, N., Sumitani, S., Tomotake, M., Kaneda, Y., Taniguchi, T., Ishimoto, Y., and Ohmori, T. (2006). Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 401, 1-5.
50. Onogi, H., Nakagawasai, O., Sato, A., Mitazaki, S., Nakaya, K., Watanabe, K., Niijima-Yaoita, F., Tan-No, K., Arai, Y., Kikuchi, T., and Tadano, T. (2011). p- Hydroxyamphetamine causes prepulse inhibition disruption in mice: contribution of serotonin neurotransmission. Behav Brain Res 224, 159-165.
51. Onogi, H., Nakagawasai, O., Tan-No, K., Mitazaki, S., Sato, A., Nakaya, K., Niijima, F., Arai, Y., Kikuchi, T., and Tadano, T. (2010). p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission. Behav Brain Res 214, 349-356.
52. Perry, W., and Braff, D.L. (1994). Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 151, 363-367.
53. Pogorelov, V.M., Nomura, J., Kim, J., Kannan, G., Ayhan, Y., Yang, C., Taniguchi, Y., Abazyan, B., Valentine, H., Krasnova, I.N., Kamiya, A., Cadet, J.L., Wong, D.F., and Pletnikov, M.V. (2012). Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference: a comorbidity model. Neuropharmacology 62, 1242-1251.
54. Powell, S.B., Zhou, X., and Geyer, M.A. (2009). Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204, 282-294.
55. Robinson, T.E., and Camp, D.M. (1987). Long-lasting effects of escalating doses of damphetamine on brain monoamines, amphetamine-induced stereotyped behavior and spontaneous nocturnal locomotion. Pharmacol Biochem Behav 26, 821-827.
56. Rybakowski, J.K., Borkowska, A., Skibinska, M., Szczepankiewicz, A., Kapelski, P., Leszczynska-Rodziewicz, A., Czerski, P.M., and Hauser, J. (2006). Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci 60, 70-76.
57. Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., Macdonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., Ernfors, P., and Castren, E. (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23, 349-357.
58. Sato, M., Numachi, Y., and Hamamura, T. (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 18, 115-122.
59. Saylor, A.J., and Mcginty, J.F. (2008). Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav 7, 906-914.
60. Sim, M.S., Mohamed, Z., Hatim, A., Rajagopal, V.L., and Habil, M.H. (2010). Association of brain-derived neurotrophic factor (Val66Met) genetic polymorphism with methamphetamine dependence in a Malaysian population. Brain Res 1357, 91-96.
61. Smith, G.N., Thornton, A.E., Lang, D.J., Macewan, G.W., Ehmann, T.S., Kopala, L.C., Tee, K., Shiau, G., Voineskos, A.N., Kennedy, J.L., and Honer, W.G. (2012). Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophr Res 134, 253-259.
62. Sulzer, D., Sonders, M.S., Poulsen, N.W., and Galli, A. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75, 406-433.
63. Swerdlow, N.R., Light, G.A., Cadenhead, K.S., Sprock, J., Hsieh, M.H., and Braff, D.L. (2006). Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63, 1325-1335.
64. Szeszko, P.R., Lipsky, R., Mentschel, C., Robinson, D., Gunduz-Bruce, H., Sevy, S., Ashtari, M., Napolitano, B., Bilder, R.M., Kane, J.M., Goldman, D., and Malhotra, A.K. (2005). Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 10, 631-636.
65. Takahashi, M., Shirakawa, O., Toyooka, K., Kitamura, N., Hashimoto, T., Maeda, K., Koizumi, S., Wakabayashi, K., Takahashi, H., Someya, T., and Nawa, H. (2000). Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5, 293-300.
66. Thompson Ray, M., Weickert, C.S., Wyatt, E., and Webster, M.J. (2011). Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 36, 195-203.
67. Van Den Buuse, M. (2010). Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects. Schizophr Bull 36, 246-270.
68. Van Den Buuse, M., Morris, M., Chavez, C., Martin, S., and Wang, J. (2004). Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice. Br J Pharmacol 142, 543-550.
69. Van Den Buuse, M., Wischhof, L., Lee, R.X., Martin, S., and Karl, T. (2009). Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 12, 1383-1393.
70. Wang, J.H., Short, J., Ledent, C., Lawrence, A.J., and Van Den Buuse, M. (2003). Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav Brain Res 143, 201-207.
71. Weickert, C.S., Hyde, T.M., Lipska, B.K., Herman, M.M., Weinberger, D.R., and Kleinman, J.E. (2003). Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8, 592-610.
72. Willott, J.F., Tanner, L., O'steen, J., Johnson, K.R., Bogue, M.A., and Gagnon, L. (2003). Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav Neurosci 117, 716-727.
73. Wong, J., Hyde, T.M., Cassano, H.L., Deep-Soboslay, A., Kleinman, J.E., and Weickert, C.S. (2010). Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 169, 1071-1084.
74. Wu, Y.W., Hill, R.A., Gogos, A., and Van Den Buuse, M. (2012). Sex differences and the role of estrogen in animal models of schizophrenia: Interaction with BDNF. Neuroscience.
75. Zhou, D.H., Yan, Q.Z., Yan, X.M., Li, C.B., Fang, H., Zheng, Y.L., Zhang, C.X., Yao, H.J., Chen Da, C., Xiu, M.H., Kosten, T.R., and Zhang, X.Y. (2010). The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 34, 930-933.